NCT06136104

Brief Summary

The purpose of this study is to assess Mixhers HERTIME supplements efficacy in alleviating menstrual cycle symptoms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Aug 2023

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 30, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 27, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2023

Completed
Last Updated

May 8, 2024

Status Verified

November 1, 2023

Enrollment Period

4 months

First QC Date

October 27, 2023

Last Update Submit

May 7, 2024

Conditions

Keywords

PMS (Premenstrual syndrome)PMDD (Premenstrual dysphoric disorder)Period SymptomsMenstrual CycleMenstrual CrampingMenstrual Bleeding

Outcome Measures

Primary Outcomes (5)

  • Menstrual Cramping and/or Back Pain

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

    120 days

  • Mood Regulation

    Measured through post-menstrual bleeding electronic survey 1-10 mood scale

    120 days

  • Bloating

    Measured through post-menstrual bleeding electronic survey 1-10 severity scale

    120 days

  • Menstrual Bleeding Volume

    Measured through post-menstrual bleeding electronic survey 1-10 scale of flow volume

    120 days

  • Menstrual Bleeding Duration

    Measured through post-menstrual bleeding electronic survey recording start and end day of menstrual bleeding

    120 days

Secondary Outcomes (13)

  • Fatigue

    120 days

  • Acne

    120 days

  • Difficulty Concentrating

    120 days

  • Overeating/Food Cravings

    120 days

  • Insomnia

    120 days

  • +8 more secondary outcomes

Other Outcomes (1)

  • Other miscellaneous changes noticed during menstrual bleeding

    120 days

Study Arms (2)

Mixhers HERTIME

EXPERIMENTAL

1 daily powder stick packet (3.0-3.3 g) of Mixhers HERTIME herbal supplement mixed into water

Dietary Supplement: Mixhers HERTIME

Placebo

PLACEBO COMPARATOR

1 daily powder stick packet (3 g) of a matching placebo powder supplement mixed into water

Dietary Supplement: Placebo

Interventions

Mixhers HERTIMEDIETARY_SUPPLEMENT

A daily self-administered powder supplement packet mixed into water.

Mixhers HERTIME
PlaceboDIETARY_SUPPLEMENT

A daily self-administered powder placebo supplement packet mixed into water.

Placebo

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Must be biologically female, must have a regular menstrual cycle (defined as a menstrual bleed every 23-35 days), must be a student, staff, or faculty member at Midwestern University Glendale, Arizona campus

You may not qualify if:

  • not pregnant or planning to become pregnant, must not be on anticoagulants, must not have allergies to lemon or stevia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Midwestern University

Glendale, Arizona, 85308, United States

Location

MeSH Terms

Conditions

Premenstrual Dysphoric DisorderPremenstrual Syndrome

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsDepressive DisorderMood DisordersMental Disorders

Study Officials

  • Farshad Agahi, MD

    Midwestern University- Glendale, AZ

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 27, 2023

First Posted

November 18, 2023

Study Start

August 30, 2023

Primary Completion

December 20, 2023

Study Completion

December 20, 2023

Last Updated

May 8, 2024

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations